Oculus Innovative Sciences Reports Third Quarter FY 2010 Financial Results: 30% Reduction in Operating Expenses and 36% Increase in Product Revenue Feb 4, 2010
Oculus Innovative Sciences Introduces Microcyn(R) Solution for Use in Post-Surgical Wounds to U.S. Hospitals and Physicians Jan 28, 2010
Oculus Innovative Sciences Announces Fiscal Third Quarter 2010 Financial Results and Corporate Update Release and Conference Call Jan 26, 2010
Oculus Innovative Sciences to Present at OneMed Forum 2010 During JP Morgan Week in San Francisco Jan 7, 2010
Oculus Innovative Sciences' Development Partner, Bayer Animal Health, Receives Regulatory Approvals to Market Microcyn(R)-Based Vetericyn(TM) Animal Healthcare Products in China and Taiwan Nov 13, 2009
Oculus Innovative Sciences Reports Second Quarter FY 2010: 60% Reduction in Operating Expenses and 16% Increase in Product Revenue (37% in Local Currency) Nov 5, 2009
Oculus Innovative Sciences Announces Fiscal Second Quarter 2010 Financial Results and Corporate Update Release and Conference Call Oct 22, 2009
Oculus Innovative Sciences Rolls Out Microcyn(R) HydroGel Skin and Wound Care Products for Both U.S. Healthcare Professionals and Consumers Sep 28, 2009
Oculus Innovative Sciences Announces New Partnership Agreement with V&M Industries, Inc. for Microcyn(R)-Based OTC Human Wound Care Products Sep 16, 2009
